|
Volume 71 of Advances in Cancer Research begins with Morgan and Kastan presenting data on the roles of p53 and ATM in cell cycle progression and cell death in response to DNA damage and how this information may lead to targets for improved cancer therapies. Kok et all. Review the methodological advantages and limitations to localizing tumor suppressor genes, especially those on the short arm of chromosome 3. Peltomaki and de la Chapelle describe research on mismatch repair genes and their effects on colorectal cancer. McKenna and Cotter present findings on the functions and failures of apoptosis in the hematopoietic system. Ravitz and Wenner review TGF-B and how it controls and affects cell cycle progression in a variety of cell types. Andrew Simpson presents data on the mutation frequencies of microsatellites in human carcinogenesis. Naor and colleagues present research on a multitude of tumors expressing levels of CD44 and discuss how CD44 may be used as a target for cancer therapy. Luisa Villa discusses various aspects of HPV and the potential clinical use of HPV testing in cervical cancer prevention programs. Last, Disis and Cheever review the studies that define HER-2/neu specific immunity in patients with cancer and the current vaccine strategies for generating specific immunity.
- Front Cover
- Advances in Cancer Research, Volume 71
- Copyright Page
- Contents
- Contributors to Volume 71
- Part I: FOUNDATIONS IN CANCER RESEARCH
- Chapter 1. p53 and ATM: Cell Cycle, Cell Death, and Cancer
- I. Introduction
- II. The p53 Tumor Suppressor Gene
- III. ATM
- IV. Cell Cycle Control
- References
- Chapter 2. Deletions of the Short Arm of Chromosome 3 in Solid Tumors and the Search for Suppressor Genes
- I. Tumor Suppressor Genes: The Concept
- II. Methods of Localizing Tumor Suppressor Genes
- III. Chromosome 3 Losses in Different Types of Tumors
- IV. Functional Assays of Tumor Suppression on Chromosome 3
- V. (Presumed) Tumor Suppressor Genes on the Short Arm of Chromosome 3
- VI. Evolutionary Aspects of Human Chromosome 3
- VII. Concluding Remarks
- References
- Chapter 3. Mutations Predisposing to Hereditary Nonpolyposis Colorectal Cancer
- I. Introduction
- II. The HNPCC Syndrome
- III. HNPCC and DNA MMR
- IV. Mutations Predisposing to HNPCC
- V. Phenotypic Effects of MMR Gene Mutations
- VI. Implications of Mutation Findings
- References
- Chapter 4. Functional Aspects of Apoptosis in Hematopoiesis and Consequences of Failure
- I. Introduction
- II. Morphological and Biochemical Features of Apoptosis
- III. Molecular Mechanisms in Apoptosis
- IV. Functional Aspects of Apoptosis in the Hematopoietic System
- V. Disruption of Apoptosis in Hematopoiesis
- VI. Future Perspectives
- References
- Chapter 5. Cyclin-Dependent Kinase Regulation during G 1 Phase and Cell Cycle Regulation by TGF-ß
- I. Introduction
- II. Cyclins and Cyclin-Dependent Kinases
- III. Conclusions
- References
- Chapter 6. The Natural Somatic Mutation Frequency and Human Carcinogenesis
- I. Introduction
- II. Somatic Mutation of Microsatellite Sequences
- III. Somatic Mutations of Minisatellite Sequences
- IV. Somatic Mutation of the HPRT Gene
- V. The Frequency of Somatic Mutation in Solid Tissues Can Account for Multistep Carcinogenesis
- VI. Cellular Proliferation as a Risk Factor for Cancer
- VII. Germline Mutations
- VIII. The Mutation Rate as the Fundamental Biological Pacemaker
- IX. The Importance of Measuring Somatic Mutation Rates
- X. The Mutational Clock and Cancer Prevention
- References
- Chapter 7. CD44: Structure, Function, and Association with the Malignant Process
- I. Introduction
- II. CD44 Nomenclature
- III. CD44 Biochemical Structure
- IV. CD44 Expression on Normal Cells
- V. Hyaluronic Acid Is the Principal Ligand of CD44
- VI. Non-HA Ligands of CD44
- VII. Soluble CD44
- VIII. Genetic Control of CD44 Expression
- IX. CD44 Functions
- X. Involvement of CD44 in Physiological and Pathological Cell Activities
- XI. CD44 Association with the Malignant Process in Experimental Models
- XII. CD44 Expression in Human Neoplasms and Its Correlation with the Malignant Status
- XIII. CD44 Association with Malignancy: Some Practical Comments
- XIV. Conclusions
- References
- Chapter 8. Human Papillomaviruses and Cervical Cancer
- I. Introduction
- II. Biology of Papillomaviruses
- III. Taxonomy and Genomic Variability of Papillomaviruses
- IV. Epidemiological Aspects
- V. HPV Interaction with Cofactors
- VI. Viral Persistence and Disease Progression
- VII. Viral Burden and Cervical Disease
- VIII. HPV in Cervical Screening Programs
- References
- Chapter 9. HER-2/neu Protein: A Target for Antigen-Specific Immunotherapy of Human Cancer
- I. Introduction
- II. HER-2/neu Vaccines For Cancer Therapy
- III. Potential Pitfalls Associated with HER-2/neu-Specific Immunotherapy
- IV. HER-2/neu-Specific Antibodies for Cancer Therapy
- V. Conclusion
- References
- Index
|
